The biopharma world's manufacturing weekly

Endpoints Manufacturing

Manufacturing channel feed

RoslinCT to com­mer­cial­ly man­u­fac­ture CRISPR-edit­ed ther­a­py Cas­gevy af­ter col­lab ex­ten­sion with Ver­tex, CRISPR

22 hours ago

US gov­ern­ment turns to more do­mes­tic phar­ma man­u­fac­tur­ing to im­prove sup­ply chain re­silience 

Yesterday
Pharma

No­vo Nordisk in­vests $2.4B in French fa­cil­i­ty to ad­dress boom­ing GLP-1 de­mand

Yesterday

Re­ci­pharm to change CEOs, spin out in­haler busi­ness

6 days ago

FDA warns Cipla's al­buterol in­haler plant af­ter thou­sands of com­plaints

Last week
R&D
FDA+

GSK boosts low-car­bon in­haler de­vel­op­ment with PhI­II tri­als, in­vest­ment in French man­u­fac­tur­ing fa­cil­i­ty 

Last week
Pharma

Bay­er re­calls one lot of sol­id tu­mor drug Vi­t­rakvi af­ter find­ing mi­cro­bial con­t­a­m­i­na­tion

Last week
Pharma

CD­MOs in­ves­ti­gate how to sup­port GLP-1 man­u­fac­tur­ing, phar­ma con­sid­ers sup­ply chain di­ver­si­ty: #Jef­feries23

Last week

Lil­ly in­vests $2.5B in new Ger­man site to boost tirzepatide sup­ply, $100M for lo­cal biotechs

Last week
R&D

As­traZeneca sub­sidiary to sell its Ban­ga­lore site, to hunt for ex­ter­nal man­u­fac­tur­er 

Last week

San­doz opens two new fa­cil­i­ties; Gates Foun­da­tion funds nee­dle-free vac­cines; No­var­tis ex­pands Japan­ese site

Last week

Ozem­pic short­ages have Eu­ro­pean coun­tries ex­plor­ing bans on use of pop­u­lar drug for weight loss

Last week
Pharma

Is the worst over? Catal­ent touts GLP-1 and gene ther­a­py busi­ness as it sticks to fi­nan­cial guid­ance

Last week

Ex­clu­sive: NTx rais­es $47.5M Se­ries B to com­mer­cial­ize pro­tein, mR­NA man­u­fac­tur­ing plat­forms 

Last week
Financing

Aji­nomo­to to buy gene ther­a­py CD­MO Forge Bi­o­log­ics in $620M all-cash deal

3 weeks ago
Deals

Ther­mo Fish­er plans to lay off 97 em­ploy­ees, close fa­cil­i­ty in Al­aba­ma

3 weeks ago
People

No­vo in­vests $6B+ to ex­pand man­u­fac­tur­ing fa­cil­i­ties as de­mand for We­govy sky­rock­ets

3 weeks ago
Pharma
Cell/Gene Tx

Cam­brex sells drug prod­uct busi­ness; Land­mark to work with Gala­pa­gos; Genezen locks $18.5M eq­ui­ty boost 

3 weeks ago

Com­mer­cial-stage man­u­fac­tur­ing key for CD­MOs as biotech fund­ing pull­back con­tin­ues, Fu­ji­film Diosynth CEO says

3 weeks ago

Charles Riv­er’s CD­MO busi­ness slows; Lil­ly boosts GLP-1 ca­pac­i­ty; Te­va’s Is­rael sites 'u­naf­fect­ed'

3 weeks ago

So­ci­etal CD­MO trims pro­ject­ed 2023 sales rev­enue de­spite third-quar­ter earn­ings bump

3 weeks ago

WuXi XDC eyes IPO to boost ADC, bio­con­ju­gate man­u­fac­tur­ing foot­print

3 weeks ago
Financing

'Pull every lev­er': Marks dou­bles down on ur­gency to im­prove gene ther­a­py man­u­fac­tur­ing

4 weeks ago
Pharma
Cell/Gene Tx

Up­dat­ed: Cel­lares to pro­duce Ca­balet­ta’s au­toim­mune CAR-T can­di­date 

4 weeks ago
Deals
1234 Next page Last page
A service from the Financial Times